EUVIMEDEUVIMED entdecken
LeitlinieÜbersichtsarbeit

Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm

Debopam Samanta, Sonam Bhalla, Sonal Bhatia, Anthony L Fine, Babitha Haridas, Cemal Karakas, Cynthia Guadalupe Keator, Hyun Yong Koh, M Scott Perry, Carl E Stafstrom, Jorge Vidaurre, Aaron E L Warren

Epilepsy & Behavior · 2025-03 · 164 · 110261

DOI: 10.1016/j.yebeh.2024.110261 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Epilepsy & Behavior, 2025-03. Verfasst von Debopam Samanta und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Child Neurology, Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA. Electronic address: dsamant…. Hauptthemen laut MEDLINE: Algorithms, Anticonvulsants, Lennox Gastaut Syndrome. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 156 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lennox-Gastaut syndrome (LGS) is a severe, childhood-onset developmental and epileptic encephalopathy characterized by multiple drug-resistant seizure types, specific electroencephalogram (EEG) patterns, and significant cognitive and behavioral impairments. To date, eight anti-seizure medications (ASMs) have been specifically approved by the U.S. Food and Drug Administration (FDA) for the treatment of LGS: clonazepam, felbamate, lamotrigine, topiramate, rufinamide, clobazam, cannabidiol, and fenfluramine. Additionally, several other ASMs, including valproate, are frequently used off-label for LGS management. As the therapeutic landscape for LGS expands, clinicians are increasingly faced with complex decisions regarding optimal ASM selection. This narrative review explores evolving treatment strategies, offering a consensus-based treatment algorithm designed by a panel of U.S.- based experts. We analyze both FDA-approved and off-label ASMs, drawing on data from randomized controlled trials, open-label extensions, and real-world studies to assess each drug's efficacy and safety profile. A key challenge in comparing ASMs lies in the heterogeneity of study designs and outcome measures. This review addresses these limitations and considers crucial factors influencing ASM selection, such as seizure outcomes, safety profiles, cognitive and behavioral outcomes, drug-drug interactions, and rational polypharmacy. Barriers to access, including economic and regulatory hurdles, are also discussed. The proposed treatment algorithm emphasizes a personalized approach to LGS management, recommending valproate or clobazam as first-line treatments, followed by individualized combinations based on the specific patient profile and associated comorbidities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlgorithmsAnticonvulsantsLennox Gastaut SyndromeHumansConsensus

Substanzen

Anticonvulsants

Autor:innen und Institutionen

  • Division of Child Neurology, Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA. Electronic address: dsamanta@uams.edu.
  • Division of Child Neurology, Emory University/Children's Healthcare of Atlanta, USA.
  • Department of Pediatrics, Division of Pediatric Neurology, Shawn Jenkins Children's Hospital and Medical University of South Carolina, Charleston, SC, USA.
  • Division of Child and Adolescent Neurology, Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.
  • Division of Pediatric Neurology, Department of Pediatrics, Norton Children's Hospital, University of Louisville, Louisville, KY 40202, USA.

Zitieren

APA

Samanta, D., Bhalla, S., Bhatia, S., Fine, A. L., Haridas, B., Karakas, C., Keator, C. G., Koh, H. Y., Perry, M. S., Stafstrom, C. E., Vidaurre, J., & Warren, A. E. L. (2025). Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm. Epilepsy & Behavior, 164, 110261. https://doi.org/10.1016/j.yebeh.2024.110261

Vancouver

Samanta D, Bhalla S, Bhatia S, Fine AL, Haridas B, Karakas C, et al. Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm. Epilepsy & Behavior. 2025;164:110261. doi:10.1016/j.yebeh.2024.110261

BibTeX
@article{Samanta2025,
  author = {Samanta, Debopam and Bhalla, Sonam and Bhatia, Sonal and Fine, Anthony L and Haridas, Babitha and Karakas, Cemal and Keator, Cynthia Guadalupe and Koh, Hyun Yong and Perry, M Scott and Stafstrom, Carl E and Vidaurre, Jorge and Warren, Aaron E L},
  title = {Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm},
  journal = {Epilepsy & Behavior},
  year = {2025},
  volume = {164},
  pages = {110261},
  doi = {10.1016/j.yebeh.2024.110261}
}
Kostenlos starten →